2006NLA他汀肝臟安全性評估共識
《2006NLA他汀肝臟安全性評估共識》內容簡介：
This has been consistently dem-onstrated in clinical trials performed during statin phase 2and 3 development programs and in long-term, end pointtrials.1The prescribing ***rmation for each statin citesthese associations. Aminotransferase elevations 3 timesthe upper limit of normal generally occur in 1% of pa-tients across the dose range for marketed statins; the excep-tions are aminotransferase elevations of this magnitude thatoccur in 2%–3% of patients receiving atorvastatin 80 mg/day or the combination of ezetimibe and a statin.
《2006NLA他汀肝臟安全性評估共識》內容預覽：
Are statin-associated elevations in aminotransferase
levels indicative of liver damage or dysfunction?
● Response: No
● Confidence/level of evidence: 2C
RATIONALE. Isolated elevations of aminotransferases in theabsence of increased bilirubin levels have not been linkedclinically or histologically with evidence of acute or chronicliver injury.6 - 8Other mechanisms have been proposed thatcould explain commonly observed aminotransferase elevationsin individuals treated with statins, including a transient phar-macologic effect secondary to cholesterol reduction in hepato-cytes, comorbid conditions such as diabetes mellitus and obe-sity, and the consumption of alcohol or nonstatin medications.6Are statin-associated elevations in aminotransferasesa class effect?
● Response: Yes
● Confidence/level of evidence: 1A
RATIONALE. The Liver Expert Panel affirms that eleva-tions in aminotransferase levels have been reported with alldoses of all marketed statins and that no particular statinappears to cause these elevations more frequently than oth-ers. This observation is supported by the official productlabeling for each marketed statin2,3,9 -13and by long-termrandomized end point trials.1A recent meta-**ysis of 13of these clinical trials, involving 49,275 patients, supportsthis assertion.14Whereas fluvastatin demonstrated statisti-cally significant higher aminotransferase elevations at cer-tain doses in this meta-**ysis, the Panel was not persuadedthat this difference is clinically significant.
點擊下載***：《2006NLA他汀肝臟安全性評估共識》
本站所注明來源為"愛愛醫(yī)"的文章，版權歸作者與本站共同所有，非經(jīng)授權不得轉載。
本站所有轉載文章系出于傳遞更多信息之目的，且明確注明來源和作者，不希望被轉載的媒體或個人可與我們
聯(lián)系zlzs@120.net，我們將立即進行刪除處理
熱點圖文
-
參與應激后高代謝反應的主要因素是什么?
研究表明,機體在創(chuàng)傷、感染等應激后出現(xiàn)的以分解代謝占優(yōu)勢的高代謝狀態(tài)的主要...[詳細]
-
創(chuàng)傷、感染后的生理與代謝改變主要有哪些?
機體在遭受感染、創(chuàng)傷、大出血、大手術等打擊后將發(fā)生以高代謝狀態(tài)為特征的應激...[詳細]
